Alveolar hemorrhage associated with pemetrexed administration

Area of Science:

• Oncology
• Pulmonology
• Clinical Medicine

Background:

• Pemetrexed is a chemotherapy agent commonly used for non-small cell lung cancer.
• Alveolar hemorrhage (AH) is a serious pulmonary condition characterized by bleeding into the alveoli.
• Drug-induced lung injury is a known but often under-recognized complication of cancer therapy.

Observation:

• A 67-year-old male patient with advanced lung adenocarcinoma developed hemoptysis, dyspnea, and anemia.
• The patient had received multiple cycles of pemetrexed combined with carboplatin, followed by pemetrexed maintenance therapy.
• Chest imaging revealed diffuse ground-glass opacities, suggestive of an acute pulmonary process.

Findings:

• The patient was diagnosed with alveolar hemorrhage (AH) based on bronchoalveolar lavage (BAL) findings.
• Diagnostic evidence included bloody BAL fluid, the presence of hemosiderin-laden macrophages, and confirmation via transbronchial lung biopsy.
• This represents the first documented instance of AH causally associated with pemetrexed treatment.

Implications:

• This case highlights a potential new adverse effect of pemetrexed, necessitating increased clinical vigilance.
• Physicians should consider AH in patients on pemetrexed presenting with respiratory symptoms and anemia.
• Further research is warranted to elucidate the mechanism and incidence of pemetrexed-induced AH.